c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy

Front Biosci (Landmark Ed). 2009 Jan 1;14:3401-8. doi: 10.2741/3461.

Abstract

Based on the genetic background of cancer, we have been trying to develop novel diagnostic and therapeutic strategies against human cancers. c-myc gene activation has been detected in many human cancers, indicating a key role of c-myc in tumor development. Thus targeting c-myc gene suppression is a promising strategy for cancer treatment. Recently, an interaction between FIR (FUSE-Binding Protein-Interacting Repressor) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and so might be important for suppressing tumor formation. Previously, we have shown that the expression of splicing variant of FIR is elevated in colorectal cancer tissues and promotes tumor development by disabling FIR-repression to sustain high levels of c-Myc, opposing apoptosis in cancer cells. In this study, FIR recombinant adenovirus vector induces tumor growth suppression against tumor xenografts in animal model experiment. Together, one clue to the development of cancer diagnosis and therapies directed against c-Myc may go through FIR and its splicing variant.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alternative Splicing
  • Amino Acid Sequence
  • Animals
  • Apoptosis
  • Base Sequence
  • DNA Primers
  • Genes, myc*
  • HeLa Cells
  • Humans
  • Immunohistochemistry
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Molecular Sequence Data
  • Neoplasms / diagnosis*
  • Neoplasms / therapy*
  • RNA Splicing Factors
  • RNA-Binding Proteins
  • Repressor Proteins / metabolism*
  • Repressor Proteins / therapeutic use
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • DNA Primers
  • RNA Splicing Factors
  • RNA-Binding Proteins
  • Repressor Proteins
  • poly-U binding splicing factor 60KDa